Stock 4882 PERSEUS PROTEOMICS INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News Perseus Proteomics Inc.

Equities

4882

JP3836800007

Delayed Japan Exchange
Other stock markets
 06:17:36 16/05/2024 BST 		5-day change 1st Jan Change
308 JPY -6.95% Intraday chart for Perseus Proteomics Inc. -8.93% -50.49%
05-10 Perseus Proteomics Inc. Announces on Delay in the End of Phase I Clinical Trial for Polycythemia Vera CI
03-07 Perseus Proteomics Inc. announced that it has received ¥1.566 million in funding from Barclays Bank PLC (Tokyo Branch) CI

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Perseus Proteomics Inc. Announces on Delay in the End of Phase I Clinical Trial for Polycythemia Vera
CI
Perseus Proteomics Inc. announced that it has received ¥1.566 million in funding from Barclays Bank PLC (Tokyo Branch)
CI
Perseus Proteomics Inc. announced that it expects to receive ¥1.566 million in funding
CI
Perseus Proteomics Inc. Reports Earnings Results for the Nine Months Ended December 31, 2023
CI
Perseus Proteomics Inc. Announces on Delay in the End of Phase I Clinical Trial for Polycythemia Vera
CI
Perseus Proteomics Secures Japanese Patent for Blood Cancer Drug Candidate
MT
Perseus Proteomics Inc. Reports Earnings Results for the Half Year Ended September 30, 2023
CI
Perseus Proteomics Successfully Enrolls Patients in Phase I Clinical Trial of Anti-TfR1 Antibody for Polycythemia Vera
MT
Perseus Proteomics Inc. Announces Completion of Patients Enrollment in Phase I Clinical Trial for Polycythemia Vera (PV)
CI
Perseus Proteomics Launches Sales of Three Antibodies
MT
Perseus Proteomics Inc. Announces Sales Launch of New Antibodies/Reagents
CI
Perseus Proteomics, Inc. Announces Provision of Antibody Research Support Service Through Single Cell Cloning Technology
CI
Perseus Proteomics Inc. Announces on Dosing of the First Patient in Phase I/II Clinical Trial for Aggressive NK-Cell Leukemia
CI
Perseus Proteomics, Inc. Announces MOU Agreement on Joint Research on Super-Neutralizing Antibody with University of Toyama and Toyama Prefecture
CI
Perseus Proteomics Inc. Reports Impairment Loss for the First Quarter of the Fiscal Year 2023
CI
Perseus Proteomics Inc. Provides Earnings Guidance for the Fiscal Year Ending March 31, 2024
CI
Perseus Proteomics Inc. Reports Earnings Results for the First Quarter Ended June 30, 2023
CI
Perseus Proteomics Inc. Announces the Interim Report of Phase I Clinical Trial of PPMX-T003
CI
Perseus Proteomics Inc. Provides Earnings Guidance for the Fiscal Year Ending March 31, 2024
CI
Perseus Proteomics Inc. Reports Earnings Results for the Full Year Ended March 31, 2023
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 4882 Stock
  4. News Perseus Proteomics Inc.